Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
12 Doses of Uptravi 1000 MCG Tablets (GENERIC SELEXIPAG) for VA San Diego is a federal award for 262-Network Contract Office 22 (36C262) held by Actelion Pharmaceuticals Us Inc. Estimated value $172K ($172K obligated). Current period of performance ends Oct 5, 2023. Last award drew 1 bidder. Place of performance: LAKE MARY FL.
12 doses of uptravi 1000 mcg tablets (generic selexipag) for va san diego. Latest action is a modification.
Recompete timing
PublicCurrent PoP ended Oct 5, 2023 (1112 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 36C26222F0620? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordActelion Pharmaceuticals Us Inc — $5.4M obligated across 106 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C26222F0620?
36C26222F0620 (12 doses of uptravi 1000 MCG) is a 262-Network Contract Office 22 (36C262) award with a potential value of $172K, currently held by Actelion Pharmaceuticals Us Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C262-22-F-0620?
36C262-22-F-0620 is the dashed form of PIID 36C26222F0620 (12 doses of uptravi 1000 MCG), held by Actelion Pharmaceuticals Us Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C26222F0620?
262-Network Contract Office 22 (36C262) awarded 36C26222F0620 to Actelion Pharmaceuticals Us Inc (potential $172K).
Who is the incumbent on 36C26222F0620?
Actelion Pharmaceuticals Us Inc is the incumbent with $5.4M across 106 related awards in SCOUT’s public footprint. The current period of performance ends Oct 5, 2023.
When does Actelion Pharmaceuticals Us Inc’s 36C26222F0620 come up for recompete?
SCOUT tracks a period-of-performance end of Oct 5, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C26222F0620? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.